During the past 3 years, the average Free Cash Flow per Share Growth Rate was 5.90% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 2.60% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was 20.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of XTL Biopharmaceuticals was 66.90% per year. The lowest was -106.50% per year. And the median was 19.50% per year.
Competitive Comparison of XTL Biopharmaceuticals's 3-Year FCF Growth Rate
For the Biotechnology subindustry, XTL Biopharmaceuticals's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XTL Biopharmaceuticals's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where XTL Biopharmaceuticals's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
XTL Biopharmaceuticals 3-Year FCF Growth Rate Related Terms
Thank you for viewing the detailed overview of XTL Biopharmaceuticals's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
XTL Biopharmaceuticals (XTL Biopharmaceuticals) Business Description
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XTLB has been successfully added to your